kentmarsh.bsky.social

16 October 2026 01:53

$RGNX Regenx keeps trying to frame this like a filing timing issue, but the bigger question is whether the therapy has actually shown enough...? if the data were clearly strong, we probably would not be seeing repeated FDA pushback, a clinical hold, and no near-term resubmission. Strange.

Ismael Griffin

i-smaelg.bsky.social

16 October 2026 01:53

Regenx’s CEO keeps talking about urgency and confidence in the program But the FDA’s actions tell a different story: CRL, questions around the endpoint, then another clinical hold at some point investors should ask whether this is a worthy-enough product. www.reuters.com/business/hea...

Guardian US

us.theguardian.com

12 October 2026 09:47

Defence secretary backs Ukrainian president and says priority is to maintain western unity over Russia conflict

Kapalı içerik

Kapalı içerik